ABSTRACT
Lung ultrasonography has emerged as a promising imaging modality during the COVID-19 pandemic with potential use in triage, diagnosis, prognosis and disease progression.
This retrospective observational cohort study carried out in a busy urban Emergency Department in the United Kingdom provides a systematic analysis of lung ultrasound findings (pleural irregularities, B-lines, consolidations, pleural effusions) in SARS-CoV-2 positive patients and correlates these findings to disease severity as defined by oxygen-deficiency based on the Berlin Criteria for ARDS.
Our results show that wide B-lines, as well pleural irregularities and subpleural consolidations are frequent findings in COVID-19 disease. Lung abnormalities occur bilaterally, interspersed with normal lung, and without significant predilection for specific lung areas. Wide B-lines are a strong feature in COVID-19 infection. We also describe a finding of small localised peri-pleural effusions in 8.3% (95% C.I. 5.9-10.8%) of lung zones.
Disease severity correlates strongly to the frequency of abnormal ultrasound findings. Irregular pleura and subpleural consolidations increase from 40% (95% C.I. 33.3-46.1%) and 27.7% (C.I.95% 21.8-33.5%) of zones affected in mild disease to 85.7% (C.I.95% 79.8-91.7%) and 66.2% (C.I.95% 58.1-74.2%) in severe disease. Wide B-lines increase from 15.6% (C.I.95% 10.9-20.4%) to 45.1% (C.I.95% 36.7-53.6%). There is an inverse correlation to the amount of normal lung seen, decreasing from 57.1% (C.I.95% 50.6-63.6%) to 6% (C.I.95% 2.0-10.1%) of lung zones.
These results contribute to a more thorough understanding of the lung changes in COVID-19 pneumonia and enhance the evidence base for the application of ultrasound in triage, diagnosis, treatment, and prognosis in SARS-CoV-2 infection.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
The study is not a clinical trial, but a retrospective observational study using investigations as part of routine assessment
Funding Statement
No external funding was received for this study
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
IRAS 286015 HRA approved - REC reference: 20/HRA/3386
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
figures and statistics updated. Result section updated
Data Availability
all data is provided in the article
